Tai-seung S. Nam

Gwangju, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Application of the 2024 and 2017 McDonald criteria at disease onset in a multicenter Korean MS cohort.

Application of the 2024 and 2017 McDonald criteria at disease onset in a multicenter Korean MS cohort.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 25, 2026

Prevalence and Relative Proportions of MS, NMOSD, and MOGAD in the Republic of Korea.

Prevalence and Relative Proportions of MS, NMOSD, and MOGAD in the Republic of Korea.

Journal: Neurology

Published: May 15, 2026

Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.

Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.

Journal: Neurology

Published: March 12, 2026

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 26, 2026

Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: JAMA network open

Published: February 13, 2026

Rarity of silent progression: PIRA and RAW in myelin oligodendrocyte glycoprotein antibody-associated disease.

Rarity of silent progression: PIRA and RAW in myelin oligodendrocyte glycoprotein antibody-associated disease.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: January 13, 2026

Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.

Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 29, 2025

Homozygous CAG Repeat Expansion in Spinocerebellar Ataxia Type 6: Longitudinal Analysis of Vestibulo-Ocular Reflex Findings.

Homozygous CAG Repeat Expansion in Spinocerebellar Ataxia Type 6: Longitudinal Analysis of Vestibulo-Ocular Reflex Findings.

Journal: Cerebellum (London, England)

Published: March 25, 2025

Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea.

Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea.

Journal: Journal of clinical neurology (Seoul, Korea)

Published: November 07, 2024

Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: JAMA neurology

Published: September 03, 2024

Serial Nerve Conduction Studies in Guillain-Barré Syndrome: Its Usefulness and Precise Timing.

Serial Nerve Conduction Studies in Guillain-Barré Syndrome: Its Usefulness and Precise Timing.

Journal: Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society

Published: March 04, 2024

Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes.

Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: December 06, 2023

Showing 1-12 of 76

Last Updated: 09/26/2026